ARA 290 vs KPV
Updated November 4, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of ARA 290 and KPV (also searched as KPV vs ARA 290) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
ARA 290 centers on neuro, while KPV leans toward healing. On indexed research, ARA 290 is ahead (ARA 290: 32 studies, Human evidence; KPV: 21, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •ARA 290 is strongest for neuro; KPV for healing.
- •Evidence: ARA 290 Human evidence (32 studies) vs KPV Human evidence (21).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
ARA 290 vs KPV: side-by-side
| Metric | ARA 290 | KPV |
|---|---|---|
| Class | Neuro | Healing |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Human evidence |
| Studies indexed | 32 | 21 |
| Research level | Preclinical | Preclinical |
| Strongest effect | Neuro & mood | Healing & recovery |
| Healing & recovery | 4.0▲ | 4.0▲ |
| Muscle & body comp | 0.0 | 1.0▲ |
| Metabolic & appetite | 2.0▲ | 1.0 |
| Neuro & mood | 5.0▲ | 1.0 |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 3.0 | 4.0▲ |
| Skin & aesthetics | 0.0 | 2.0▲ |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | ARA 290 | KPV |
|---|---|---|
| Mechanism | Modulates macrophage activity and promotes anti-inflammatory cytokine release | Modulation of inflammatory responses |
| Route | Subcutaneous injection | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is ARA 290?
ARA 290, also known as a peptide derived from the erythropoietin (EPO) molecule, has garnered attention for its potential therapeutic applications, particularly in the context of nerve regeneration and protection. The peptide is designed to mimic some of the beneficial effects of EPO without eliciting the same erythropoietic activity, which can lead to unwanted side effects such as increased blood viscosity and hypertension.
Full ARA 290 profile, mechanism & studies →What is KPV?
KPV is a tripeptide composed of lysine, proline, and valine, which has been studied for its potential immunomodulatory and wound healing properties. Its mechanism of action is thought to involve the modulation of inflammatory responses, potentially through the inhibition of pro-inflammatory cytokines and promotion of anti-inflammatory pathways. KPV may also enhance the healing process by promoting angiogenesis and fibroblast proliferation, which are critical for tissue repair.
Full KPV profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Even | Both ~4.0/5 |
| Muscle | KPV | 1.0/5 effect signal |
| Metabolic | ARA 290 | 2.0/5 effect signal |
| Neuro | ARA 290 | 5.0/5 effect signal |
| Inflammation | KPV | 4.0/5 effect signal |
| Skin | KPV | 2.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack ARA 290 and KPV?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
ARA 290 vs KPV: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
ARA 290 has 32 approved studies indexed (Human evidence), and KPV has 21 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is ARA 290 or KPV better?
It depends on your goal. ARA 290 is strongest for neuro; KPV for healing. ARA 290 has more indexed studies (32). See the goal-by-goal breakdown above.
Is ARA 290 or KPV better for weight loss?
ARA 290 shows the stronger metabolic & appetite profile (2.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is ARA 290 or KPV better for muscle?
KPV leads on the muscle & body-composition axis (1.0/5).
Which has more research, ARA 290 or KPV?
ARA 290 has 32 approved studies indexed (Human evidence); KPV has 21 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack ARA 290 and KPV?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of ARA 290 vs KPV?
ARA 290: no community-reported effects logged yet. KPV: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is ARA 290 or KPV FDA-approved?
ARA 290 is a research-use compound and is not FDA-approved. KPV is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is KPV better than ARA 290?
For healing, KPV has the edge; for neuro, ARA 290 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
ARA 290 and KPV are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed November 4, 2026.